Gardner Kirby P, Aldakkak Mohammed, Tang Cha-Mei, Tsai Susan, Adams Daniel L
Creatv MicroTech, Inc., Monmouth Junction, NJ, USA.
Rutgers University, Graduate School of Biomedical Sciences, Piscataway, NJ, USA.
NPJ Precis Oncol. 2021 Mar 19;5(1):25. doi: 10.1038/s41698-021-00161-8.
Pancreatic cancer (PC) is notoriously difficult to diagnosis and properly stage resulting in incorrect primary treatment. Diagnostic and prognostic biomarkers are desperately needed to more accurately stage patients and select proper treatments. Recently, a newly discovered circulating stromal cell, i.e. cancer associated macrophage-like cell (CAML), was found to accurately identify solid cancers and predict for worse prognosis. In this pilot study, blood samples were procured from 63 PC patients prior to start of therapeutic intent. CAMLs were found in 95% of samples tested, with ≥12 CAMLs/7.5 mL and ≥50 µm CAMLs both predicting for advanced pathological stage and progression free survival. These data suggest that CAML assessment prior to treatment of PC predicts patients with under-staged disease and with more aggressive PC less likely to respond to standard of care treatment.
胰腺癌（PC）的诊断和准确分期 notoriously difficult，这会导致初始治疗不当。迫切需要诊断和预后生物标志物来更准确地对患者进行分期并选择合适的治疗方法。最近，一种新发现的循环基质细胞，即癌症相关巨噬细胞样细胞（CAML），被发现能够准确识别实体癌并预测预后较差。在这项初步研究中，在开始治疗意向之前从63例PC患者采集了血样。在95%的检测样本中发现了CAML，≥12个CAML/7.5毫升和≥50微米的CAML均预测为晚期病理分期和无进展生存期。这些数据表明，在PC治疗前进行CAML评估可预测疾病分期不足的患者以及更具侵袭性的PC患者对标准治疗反应的可能性较小。
